	US 12,128,112 B2
	Gene therapy DNA vectors based on VTVAF17
Natalia Savelieva, Wienna (AT)
Assigned to OOO “PRORYVNYE INNOVATSIONNYE TEKHNOLOGII”, Moscow (RU); and CELL AND GENE THERAPY LTD, London (GB)
Appl. No. 17/272,587
Filed by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU “PRORYVNYE INNOVATSIONNYE TEKHNOLOGII”, Moscow (RU); and CELL AND GENE THERAPY LTD, London (GB)
PCT Filed Aug. 14, 2019, PCT No. PCT/RU2019/000575 § 371(c)(1), (2) Date Mar. 1, 2021, PCT Pub. No. WO2020/050743, PCT Pub. Date Mar. 12, 2020.
Claims priority of application No. RU2018131844 (RU), filed on Sep. 5, 2018.
Prior Publication US 2021/0308282 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 48/00 (2006.01); C12N 1/20 (2006.01); C12N 15/10 (2006.01); C12N 15/70 (2006.01); C12N 15/85 (2006.01)

CPC A61K 48/005 (2013.01) [A61K 48/0016 (2013.01); C12N 1/205 (2021.05); C12N 15/1003 (2013.01); C12N 15/70 (2013.01); C12N 15/85 (2013.01)]

4 Claims

1. A DNA vector comprising DNA vector VTvaf17-SKI that has the nucleotide sequence of SEQ ID NO: 1.